美国Dyax www.dyax.com
Dyax是一家生技制药公司，专注在辨认抗体、小蛋白质和peptide化合物的药物发现临床发展，主要治疗炎症与癌症，公司拥有噬菌体显现法(Phage display)专利技术，是蛋白质表现及研究的重要技术之一。公司并开发和商业化DX - 88（ecallantide），用于治疗16岁以上遗传性血管水肿（栓塞）和其他血管性水肿的迹象。

Dyax’s mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs, while delivering outstanding value to patients and stockholders.
Strategy
Our therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation. Our powerful discovery technology provides us the uncommon advantage of being able to both identify and then develop our own clinical leads. Our integrated approach also allows us to leverage this technology into revenue generating collaborations with other companies and researchers to further their own product pipelines.
History in Brief
The company was co-founded in 1995 by biotechnology entrepreneur Henry E. Blair, presently the Chairman, President and Chief Executive Officer of Dyax Corp. Dyax Corp. was formed by the merger between Biotage, a separations instrument chromatography firm, and Protein Engineering Corporation, from which we acquired our patented proprietary phage display technology. In 2003, Dyax sold its non-core business, Biotage, to focus exclusively on biotherapeutics.
Dyax Corp. issued an initial public offering (IPO) in August 2000 and is listed on the NASDAQ exchange (Ticker: DYAX). Our company is headquartered in Cambridge, Massachusetts.
Technology
Dyax’s core proprietary phage display technology allows for the rapid identification of compounds that bind with very high affinity and specificity to therapeutic targets. Utilizing phage display, we generate large diverse libraries of human antibodies, peptides, and proteins, which may be screened against disease-associated target molecules to identify potential binders. Automation allows us to rapidly screen these libraries for high-affinity binders. Our libraries’ vast size and diversity often yield multiple candidates, from which we can quickly select the single best therapeutic candidate.